RenovoRx

What RenovoRx does

RenovoRx, Inc. is a clinical-stage biopharmaceutical company headquartered in Mountain View, California, founded in 2009 and publicly traded on Nasdaq under the ticker RNXT. The company develops targeted oncology therapies with a primary focus on locally advanced pancreatic cancer (LAPC) and other solid tumors with poor blood supply, where standard systemic intravenous chemotherapy is limited in effectiveness and accompanied by debilitating side effects. RenovoRx serves U.S. cancer centers—primarily high-volume National Cancer Institute (NCI)-designated cancer centers and academic medical centers performing interventional oncology procedures—and is expanding its commercial footprint alongside ongoing clinical development.

The company's core technology is the Trans-Arterial Micro-Perfusion (TAMP) therapy platform enabled by the patented, FDA 510(k)-cleared RenovoCath dual-balloon occlusion catheter, which received FDA clearance in 2014. The TAMP approach leverages the vasa vasorum pathway to deliver chemotherapy across the arterial wall near the tumor site, with the dual-balloon design isolating vessel sections to create localized intra-arterial pressure that drives therapeutics across the vessel wall. RenovoRx's lead investigational drug-device combination product candidate is IAG (intra-arterial gemcitabine), currently being evaluated in the Phase III TIGeR-PaC trial under FDA's 21 CFR 312 pathway. The company has secured three FDA Orphan Drug Designations—IAG for pancreatic cancer, IAG for bile duct cancer, and oxaliplatin for pancreatic cancer (granted May 2026)—each providing 7 years of market exclusivity upon NDA approval. The IP portfolio comprises 19 issued patents across multiple countries, including 9 U.S. patents and 7 pending, with the first Japanese patent allowed in April 2026.

RenovoRx generates revenue primarily through sales of the RenovoCath device as a stand-alone Class II medical device to U.S. cancer centers on a negotiated per-procedure basis. First commercial purchase orders were received in December 2024, with FY2025 revenue reaching $1.1 million and Q1 2026 revenue of $563,000 representing 136% quarter-over-quarter and 186% year-over-year growth. The company has reiterated FY2026 revenue guidance of $3-4 million. As of May 6, 2026, RenovoRx has 16 active commercial cancer center customers (up from 5 at the start of 2025) with 32 additional centers in the pipeline, targeting 36 active centers by year-end 2026. The company pursues a direct field sales motion targeting physician-to-physician advocacy at interventional oncology programs, supplemented by investigator-initiated trials, the PanTheR post-marketing registry launched July 2025, and the potential addition of a medical device commercial partner for scaled distribution.

Name

RenovoRx

Legal name

RenovoRx, Inc.

Website

https://renovorx.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

RenovoRx develops targeted oncology therapies using its TAMP platform and FDA-cleared RenovoCath dual-balloon catheter. The company serves U.S. cancer centers treating solid tumors, with primary focus on locally advanced pancreatic cancer through device commercialization and the Phase III TIGeR-PaC trial.

Ownership category

akta.pro rank

Product category

Oncology Medical Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Gastrointestinal Oncology (HLAKAFAK)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

Keywords

• Targeted drug delivery
• Oncology medical devices
• Intra-arterial chemotherapy
• Trans-arterial micro-perfusion
• Dual-balloon catheter

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. RenovoCath Device Sales: Sale of the FDA-cleared RenovoCath dual-balloon drug-delivery device as a stand-alone medical device to U.S. cancer centers. One-time hardware sales of a Class II medical device. First commercial purchase orders received December 2024. 2024 revenue: $43,000; Q4 2025 revenue: $238,000; Full year 2025 revenue: $1.1 million; Q1 2026 revenue: $563,000 (136% QoQ growth, 186% YoY growth). Reiterated full year 2026 revenue guidance of $3-4 million. Repeat-order behavior observed from existing customers. Estimated initial TAM of approximately $400 million peak annual U.S. sales opportunity for RenovoCath as a stand-alone device, with long-term several-billion-dollar potential as the platform expands into additional solid tumor indications.
2. Future Drug-Device Combination Revenue (IAG): Future potential revenue stream from the investigational drug-device combination product IAG (intra-arterial gemcitabine delivered via RenovoCath) if approved following the Phase III TIGeR-PaC clinical trial. Currently under investigation and not yet approved for commercial sale. Would offer 7 years of market exclusivity upon FDA NDA approval based on three existing Orphan Drug Designations.
3. Post-Marketing Registry Study Revenue Pathway: Launched in July 2025, the PanTheR post-marketing registry evaluates cancer treatment delivered by RenovoCath in solid tumors to expand safety and performance data, generating capital-efficient clinical evidence. The University of Vermont Cancer Center completed the first registry-eligible patient procedure, with additional sites including Baptist Health Miami Cancer Institute. This pathway may generate incremental revenue while expanding clinical evidence.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

RenovoRx develops and commercializes the FDA 510(k)-cleared RenovoCath dual-balloon catheter device and its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted intra-arterial delivery of chemotherapy to treat solid tumors. The company sells RenovoCath as a stand-alone medical device to U.S. cancer centers and is advancing the investigational drug-device combination IAG (intra-arterial gemcitabine) through the Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.

Product overview

RenovoRx develops a unified targeted oncology platform combining its FDA-cleared RenovoCath® dual-balloon drug-delivery device with its proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. The core RenovoCath device enables localized delivery of therapeutic agents directly near tumors, while the TAMP platform powers investigational drug-device combination products such as IAG (intra-arterial gemcitabine) for treating locally advanced pancreatic cancer (LAPC).

Differentiator

Problem solved

Functional benefit

Brands

• RenovoCath: FDA-cleared dual-balloon drug-delivery device for targeted local delivery of chemotherapy
• TAMP (Trans-Arterial Micro-Perfusion)
• TIGeR-PaC

Products and services

• RenovoCath Dual-Balloon Occlusion Catheter FDA 510(k)-cleared double-balloon infusion catheter designed for isolation of blood flow and delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. Indicated for temporary vessel occlusion in arteriography, preoperative occlusion, and chemotherapeutic drug infusion in arteries 3mm and larger. Sold to U.S. cancer centers as a stand-alone medical device.
• IAG (Intra-Arterial Gemcitabine) Drug-Device Combination Investigational drug-device combination oncology product candidate utilizing RenovoCath for the intra-arterial administration of gemcitabine. Regulated under FDA's 21 CFR 312 IND pathway and under investigation in the Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC).

Quantifiable outcome

• 52% reduction in tumor metabolic activity at 4-month follow-up (PET-CT) in an 82-year-old LAPC patient treated via TAMP/RenovoCath (Moffitt Cancer Center case study)
• +6 more outcomes

Named customers17 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

15 partnerships are on record, tiered minor, flagship and core.

• Alliance Global Partners (AGP)minorGTM or Marketing Partner · 20 May 2026Hosted by Scott Henry, AGP's Managing Director and Senior Healthcare Analyst. AGP Annual Healthcare Company Showcase (May 20, 2026) featured CEO Shaun Bagai and CFO Mark Voll discussing commercial progress, RenovoCath adoption, and TIGeR-PaC trial updates.
• U.S. Interventional Radiology Experts (RenovoCath Medical Advisory Board)flagshipOthers · 10 February 2026RenovoRx formed a six-member RenovoCath Medical Advisory Board comprising leading U.S. interventional radiology experts: Nadine Abi-Jaoudeh, MD (UC Irvine), Mustafa Al-Roubaie, MD (Moffitt Cancer Center), Khashayar Farsad, MD, PhD (Oregon Health & Science University), Ripal Gandhi, MD (Baptist Health South Florida), Paula Marie Novelli, MD (University of Pittsburgh Medical Center), and Jonathan Kessler, MD (City of Hope). The board provides strategic clinical insights, supports investigator-initiated trials in pancreatic cancer, and provides feedback to the sales and marketing team.
• AlphaNorth Capital EventminorGTM or Marketing Partner · 16 January 2026Investor conference held January 16-18, 2026 in Nassau, Bahamas where CEO Shaun Bagai discussed RenovoRx's progress on targeted oncology therapies and the commercialization of RenovoCath.
• iAccess AlphaminorGTM or Marketing Partner · 9 December 2025Investor conference partner hosting the Virtual Best Ideas Winter Investment Conference 2025 (December 9, 2025) and Summer Investment Conference 2026 (June 23-24, 2026) where CEO Shaun Bagai presented RenovoRx's clinical progress and commercial efforts.
• Canaccord Genuity MedTech, Diagnostics & Digital Health & Services ForumminorGTM or Marketing Partner · 20 November 2025Forum held November 20, 2025, where CEO Shaun Bagai discussed RenovoRx's clinical progress and market demand for the RenovoCath device.
• KCSA Strategic CommunicationscoreStrategic or Co-development PartnerRenovoRx's investor relations communications partner. Provides IR outreach and contact for one-on-one investor meetings. Contact: Valter Pinto or Jack Perkins, T: 212-896-1254, [email protected]. Listed as Investor Relations Contact on multiple press releases.
• STiR CommunicationscoreGTM or Marketing PartnerRenovoRx's media relations partner. Contact: Hannah Williams, T: 803-521-1214, [email protected]. Listed as Media Contact on press releases.
• Society of Interventional Radiology (SIR)coreGTM or Marketing PartnerRenovoRx regularly presents clinical data at SIR Annual Scientific Meetings. The 2026 SIR Annual Scientific Meeting in Toronto, Canada featured a clinical data abstract from Moffitt Cancer Center experts supporting RenovoRx's TAMP therapy platform. Sponsorship and presentation at SIR is a recurring element of the company's conference marketing strategy.
• American Society of Clinical Oncology (ASCO)coreGTM or Marketing PartnerRenovoRx presents Phase III TIGeR-PaC clinical trial sub-study data at ASCO meetings. The 2026 ASCO Annual Meeting (May 29 – June 2, 2026, Chicago) published online the PK/PD sub-study abstract E16463. ASCO GI Cancers Symposium 2026 also hosted RenovoRx's TIGeR-PaC sub-study data.
• Society of Interventional Oncology (SIO)coreGTM or Marketing PartnerRenovoRx regularly presents at SIO Annual Scientific Meetings. SIO 2026 (February 4-8, 2026, Savannah, GA) featured RenovoRx's findings on real-time intra-arterial pressure monitoring during TAMP procedures using RenovoCath. The conference spotlighted pain palliation, pressure monitoring, and technological innovation.
• El Camino Hospital (Mountain View, CA)minorOthersRenovoRx's CMO and Founder Dr. Ramtin Agah is an Interventional Cardiologist at El Camino Hospital, Mountain View, a role he has held since September 2005. This affiliation provides clinical expertise and proximity to RenovoRx's Mountain View headquarters.
• Abbott VascularminorOthersDr. Ramtin Agah has acted as a physician consultant for Abbott Vascular since July 2012. This is a personal consulting arrangement of the CMO and does not represent a corporate partnership between RenovoRx and Abbott Vascular.
• Moffitt Cancer CenterflagshipStrategic or Co-development PartnerMoffitt Cancer Center is a key clinical research partner. Dr. Bela Kis, MD, PhD and colleagues authored the peer-reviewed case study published in Radiology Case Reports (June 2026) demonstrating 52% reduction in tumor metabolic activity with TAMP/RenovoCath treatment. Dr. Mustafa Al-Roubaie, MD serves on RenovoRx's Medical Advisory Board. Clinical data abstracts from Moffitt experts have been presented at SIR 2026 and other major meetings.
• Scientific Advisory Board (Pancreatic Cancer and GI Oncology Experts)flagshipOthersScientific Advisory Board comprises leading pancreatic cancer and GI oncology experts: Timothy Donahue, MD (UCLA), Michel Ducreux, MD, PhD (Gustave Roussy/Paris-Saclay), Karyn A. Goodman, MD, MS (Mount Sinai), Mike Pishvaian, MD, PhD (Johns Hopkins), Margaret Tempero, MD (UCSF), and previously added Dr. Thierry de Baère (international interventional oncologist). Board provides scientific guidance on TAMP platform and RenovoCath clinical development.
• Artelo BiosciencesminorOthersPer March 23, 2026 defenseworld article, RenovoRx (NASDAQ: RNXT) and Artelo Biosciences (NASDAQ: ARTL) are small-cap medical companies compared based on earnings, risk, analyst ratings, and valuation. RenovoRx is viewed more favorably due to higher revenue, earnings, and stronger analyst recommendations. This is a competitive comparison, not a formal partnership.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• TriSalus Life Sciences: TriSalus develops the Pressure-Enabled Drug Delivery (PEDD) platform for intra-arterial delivery of therapeutics to solid tumors, including pancreatic cancer via the Limbus portal vein approach. Both companies are pursuing locally advanced pancreatic cancer with interventional oncology drug-delivery devices.
• AngioDynamics: AngioDynamics markets interventional oncology and vascular access products, including the NanoKnife irreversible electroporation system for pancreatic and other tumors. Comparable as a similarly sized public medtech focused on interventional oncology devices.
• Sirtex Medical: Sirtex develops SIR-Spheres Y-90 resin microspheres for intra-arterial radioembolization of liver tumors — a directly analogous intra-arterial, targeted-delivery oncology device. Comparable mechanism of action (localized intra-arterial therapy) and indication profile.
• DELcath Systems: DELcath develops the Melphalan/Hepatic Delivery System (CHEMOSAT) for percutaneous hepatic perfusion of liver tumors — an organ-targeted, intra-arterial drug-delivery device. Comparable as a small-cap public interventional oncology drug-device combination company.

Broad incumbents

• Boston Scientific: Boston Scientific is a major interventional oncology and peripheral vascular device incumbent and is also a RenovoRx historical investor. Comparable as a broad incumbent with overlapping interventional radiology portfolios and significantly greater scale.
• Merit Medical Systems: Merit Medical offers a broad portfolio of interventional radiology and oncology products, including embolization and drug-delivery catheters that compete in the same interventional oncology procedure suites where RenovoCath is sold.
• Penumbra: Penumbra is a publicly traded vascular and interventional thrombectomy/embolization company with overlapping call points in interventional radiology suites treating solid tumors. Comparable as a peripheral vascular interventional device incumbent.
• Medtronic: Medtronic operates a large interventional oncology and vascular franchise. RenovoRx's CEO previously led the European launch of Medtronic-acquired Ardian's renal denervation technology, and the broader Medtronic portfolio overlaps in peripheral vascular interventional devices.

Emerging players

• IceCure Medical: IceCure is a small-cap public company developing cryoablation technologies for tumor treatment, including breast and other solid tumors. Comparable as a small-cap interventional oncology device company pursuing novel localized tumor therapies.
• Taris Biomedical (a subsidiary of Bristol Myers Squibb): Taris developed intravesical drug-delivery systems for bladder cancer and was acquired by BMS. Comparable as an intra-arterial / local drug-delivery oncology platform with an exit via a major pharma acquirer — relevant precedent for RenovoRx's combination-product strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/renovorx
• Facebookfacebook.com/renovorx
• LinkedInlinkedin.com/company/renovorx

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds11 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RenovoRx